Cardiovascular benefit (reduction in MACE) has been demonstrated at this dose in T2DM patients at high CV risk (SUSTAIN-6 trial)
[4] [5] The most commonly reported adverse effects of semaglutide are gastrointestinal in nature, reflecting its mechanism of action on the digestive system
Acknowledgements The authors would like to thank the patients who participated, the investigators, all trial site staff and all Novo Nordisk employees involved in these trials
They are exciting and biologically plausible, but randomized trials specifically designed to evaluate thromboembolic outcomes would be needed before GLP-1s could be formally recommended primarily for VTE or PE prevention, Yi said.
You get safety, affordability, and convenience
Despite a still-limited understanding of dopaminergic regulation of -cells, even less is known about glucagon-secreting pancreatic -cells 16